Who We Are
Our Passion for Prevention Drives Us
Novavax has a rich history of innovation to help eradicate disease, prevent serious illness and save lives. But there is still work to be done. Our people are passionate about the mission and vision that guide our work.
Our Vision
We envision a world where our technology is amplified to touch the lives of billions, sparking transformation in global health.
Our Mission
By leveraging our science, our technology and our people, we will innovate and collaborate to tackle the world’s most significant health challenges.
Corporate Growth Strategy
Our corporate growth strategy focuses on maximizing the impact of our cutting-edge technology by forging strategic partnerships for our R&D assets and our Matrix-M® adjuvant to drive vaccine innovation that protects the health of people.
Proven Technology Platform
Our proprietary technology platform combined with our deep vaccine expertise is the fuel for future innovation and partnerships. Clinically and commercially validated, our platform features two key elements: Novavax’s recombinant protein-based nanoparticle technology and Matrix-M adjuvant.
High-Impact Pipeline
We are actively advancing our pipeline with a focus on high-value assets in areas with unmet medical need, compelling scientific rationale and strong commercial opportunity.
Maximizing Value through Partnerships
Our team is focused on what we do best: R&D with our cutting-edge technology platform. Our model creates synergy for strategic partners with the experience and business acumen to successfully commercialize these vaccines and technology.
Our Company
Novavax is committed to developing life-saving innovations that reach billions around the world.
Novavax is proudly headquartered in the USA with main offices in Gaithersburg, Maryland. We conduct R&D and manufacturing for our Matrix-M adjuvant in Uppsala, Sweden.
Meet Our Leadership
Our team has unparalleled R&D, corporate and business development experience, with deep relationships both inside and outside the industry. This immense depth of experience is ideally suited to fuel the advancement of medicines using Novavax's unique technology platform and generate partnerships with industry, government and other organizations important to our mission to prevent disease and empower people to live healthy lives.
Annual Declaration Clause for California (May 2025)
Novavax Inc. (Novavax) is committed to establishing and maintaining an effective compliance program that promotes conducting business activities in accordance with applicable laws, rules, and regulations, with the highest ethical standards in its interactions with all medical and health professionals and organizations. Novavax’ compliance program is designed to prevent, detect, and respond to potential instances of non-compliance.
Novavax declares, in good faith as of May 2, 2025, that the company is in compliance with a Comprehensive Compliance Program and the requirements of the California Health & Safety Code §119400-119402. This declaration is based on Novavax’ review and understanding of the California Health & Safety Code §119400-119402 including the key components of a Comprehensive Compliance Program and the annual aggregate limit on promotional expenditures. Novavax will update this declaration on an annual basis.
To obtain a written copy of our Code of Conduct or a written declaration of compliance, please contact 844-612-0252.
Partnerships
We forge dynamic collaborations to amplify the impact of our technology and pipeline.
People & Culture
Join us to amplify your potential and impact others.